Skip to content
Menu
About Adamas

Adamas uses its deep understanding of time-dependent biology to redefine the treatment experience for patients suffering from chronic neurological diseases.Building upon the commercial launch of GOCOVRI TM (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications and its advancing  pipeline of differentiated investigational programs, which includes ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified-release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy, Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of disease on patients, caregivers and society. Its unique expertise lies in uncovering and mapping the relationship between disease and drug activity to create medicines with therapeutic profiles that match the pattern of disease to drive a highly significant and durable clinical effect. This understanding of time-dependent biological processes informs every innovation, targeting advancement in treatment of chronic neurologic disorders.

Stock Information
NASDAQ: ADMS
$ 38.19 +0.80 (2.14%)
Day High: 38.28
Day Low:  37.44
Volume:    47,586,400
4:00 PM ET on
Jan 19, 2018

Delayed ~20 min., by eSignal.